GITRL:GITR[Biotinylated] Inhibitor Screening Assay Kit

Catalog #
72061
$1,070 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The GITR:GITRL [Biotinylated] Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of GITR:GITRL signaling. This kit comes in a convenient 96 well format, with biotin-labeled GITR (CD357), purified GITRL, streptavidin-labeled HRP, and Immunobuffer for 100 binding reactions. The key to this kit is the high sensitivity of detection of biotin-labeled GITR by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, GITRL is coated on a 96-well plate. Next, GITR is incubated with GITRL on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can be measured using a chemiluminescence reader.

Synonyms
Glucocorticoid-induced TNFR-Related Protein, Tumor Necrosis Factor Receptor Superfamily member 18, TNFRSF18, Activation-Inducible TNFR Family Receptor, AITR, and CD357, activity assay kit
Product Info
Storage and Usage
Citations
Assay Kit Format
Chemiluminescent
Format
Catalog
Number

Component

Amount

Storage
71256 GITR, Biotin-labeled 2 µg -80°C


Avoid freeze/
thaw cycles!
71190 GITRL-His 10 µg -80°C
79742 Streptavidin-HRP 15 µl +4°C
79311 3x Immunobuffer 1 50 ml -20°C
79728 Blocking Buffer 2 50 ml +4°C
79670 ELISA ECL substrate A
(transparent bottle)
6 ml RT
ELISA ECL substrate B
(brown bottle)
6 ml RT
79699 White 96-well microplate 1 +4°C
UniProt #
GITRL: Q9UNG2; GITR: Q9Y5U5
Background
Glucocorticoid-induced TNFR-related protein (GITR) is a member of the TNFR superfamily, expressed in a number of cells including T cells, natural killer (NK) cells and antigen-presenting cells (APC). GITRL, GITR’s natural ligand, is expressed mainly by APCs and GITR:GITRL interaction is important for activation of the immune system. Agonistic antibodies targeting GITR are actively being pursued as potential immuno oncology therapies.